Trade 10x Genomics, Inc. - TXG CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.14 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 47.48 |
Open* | 49.47 |
1-Year Change* | -48.43% |
Day's Range* | 49.47 - 51.79 |
52 wk Range | 23.81-100.00 |
Average Volume (10 days) | 1.10M |
Average Volume (3 months) | 26.78M |
Market Cap | 5.36B |
P/E Ratio | -100.00K |
Shares Outstanding | 114.46M |
Revenue | 503.71M |
EPS | -1.48 |
Dividend (Yield %) | N/A |
Beta | 1.73 |
Next Earnings Date | Feb 15, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 1, 2023 | 47.48 | 1.51 | 3.28% | 45.97 | 48.09 | 45.16 |
Jan 31, 2023 | 46.76 | 1.55 | 3.43% | 45.21 | 47.00 | 44.96 |
Jan 30, 2023 | 45.27 | -2.70 | -5.63% | 47.97 | 47.97 | 45.09 |
Jan 27, 2023 | 48.59 | 1.60 | 3.40% | 46.99 | 48.73 | 46.87 |
Jan 26, 2023 | 47.99 | 0.98 | 2.08% | 47.01 | 48.18 | 46.17 |
Jan 25, 2023 | 45.94 | 1.70 | 3.84% | 44.24 | 45.98 | 43.17 |
Jan 24, 2023 | 45.44 | -1.52 | -3.24% | 46.96 | 48.23 | 44.98 |
Jan 23, 2023 | 47.88 | 1.13 | 2.42% | 46.75 | 49.34 | 46.37 |
Jan 20, 2023 | 47.28 | 2.41 | 5.37% | 44.87 | 47.71 | 44.24 |
Jan 19, 2023 | 44.92 | 0.80 | 1.81% | 44.12 | 45.26 | 43.48 |
Jan 18, 2023 | 45.55 | 1.59 | 3.62% | 43.96 | 46.32 | 43.96 |
Jan 17, 2023 | 43.33 | 0.23 | 0.53% | 43.10 | 44.79 | 42.17 |
Jan 13, 2023 | 43.15 | 2.33 | 5.71% | 40.82 | 43.37 | 40.76 |
Jan 12, 2023 | 41.60 | -0.36 | -0.86% | 41.96 | 42.07 | 39.55 |
Jan 11, 2023 | 41.91 | 0.64 | 1.55% | 41.27 | 43.25 | 40.27 |
Jan 10, 2023 | 41.13 | 2.17 | 5.57% | 38.96 | 42.26 | 38.92 |
Jan 9, 2023 | 39.99 | 2.03 | 5.35% | 37.96 | 40.93 | 37.96 |
Jan 6, 2023 | 37.74 | 0.65 | 1.75% | 37.09 | 38.30 | 34.80 |
Jan 5, 2023 | 37.53 | 2.25 | 6.38% | 35.28 | 37.95 | 34.82 |
Jan 4, 2023 | 36.28 | 0.76 | 2.14% | 35.52 | 36.67 | 34.73 |
10x Genomics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Total revenue | 71.085 | 146.313 | 245.893 | 298.845 | 490.49 |
Revenue | 71.085 | 146.313 | 245.893 | 298.845 | 490.49 |
Cost of Revenue, Total | 10.56 | 28.661 | 61.033 | 58.468 | 74.091 |
Gross Profit | 60.525 | 117.652 | 184.86 | 240.377 | 416.399 |
Total Operating Expense | 89.46 | 257.077 | 276.466 | 834.508 | 542.743 |
Selling/General/Admin. Expenses, Total | 46.736 | 87.936 | 130.834 | 199.726 | 257.56 |
Research & Development | 32.164 | 109.9 | 83.097 | 570.923 | 211.752 |
Other Operating Expenses, Total | 0 | 30.58 | 1.502 | 1.27 | -0.66 |
Operating Income | -18.375 | -110.764 | -30.573 | -535.663 | -52.253 |
Interest Income (Expense), Net Non-Operating | -0.503 | -1.385 | -0.274 | -0.15 | -0.66 |
Other, Net | 0.137 | -0.249 | -0.186 | 1.337 | -0.802 |
Net Income Before Taxes | -18.741 | -112.398 | -31.033 | -534.476 | -53.715 |
Net Income After Taxes | -18.762 | -112.485 | -31.251 | -542.731 | -58.223 |
Net Income Before Extra. Items | -18.762 | -112.485 | -31.251 | -542.731 | -58.223 |
Total Extraordinary Items | 0 | ||||
Net Income | -18.762 | -112.485 | -31.251 | -542.731 | -58.223 |
Income Available to Common Excl. Extra. Items | -18.762 | -112.485 | -31.251 | -542.731 | -58.223 |
Income Available to Common Incl. Extra. Items | -18.762 | -112.485 | -31.251 | -542.731 | -58.223 |
Diluted Net Income | -18.762 | -112.485 | -31.251 | -542.731 | -58.223 |
Diluted Weighted Average Shares | 93.8497 | 93.8497 | 39.0914 | 101.152 | 110.348 |
Diluted EPS Excluding Extraordinary Items | -0.19992 | -1.19857 | -0.79943 | -5.36552 | -0.52763 |
Diluted Normalized EPS | -0.19992 | -1.19857 | -0.79943 | -5.33904 | -0.52763 |
Unusual Expense (Income) | 4.121 | 0 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 105.821 | 115.842 | 125.297 | 143.53 | 114.496 |
Revenue | 105.821 | 115.842 | 125.297 | 143.53 | 114.496 |
Cost of Revenue, Total | 17.06 | 4.915 | 24.518 | 27.598 | 25.478 |
Gross Profit | 88.761 | 110.927 | 100.779 | 115.932 | 89.018 |
Total Operating Expense | 116.037 | 126.17 | 141.176 | 159.36 | 156.231 |
Selling/General/Admin. Expenses, Total | 55.704 | 68.503 | 62.076 | 69.877 | 66.675 |
Research & Development | 41.883 | 53.402 | 54.582 | 61.885 | 64.078 |
Unusual Expense (Income) | 1.2 | 0.2 | 0 | 0 | |
Other Operating Expenses, Total | 0.19 | -0.85 | 0 | 0 | 0 |
Operating Income | -10.216 | -10.328 | -15.879 | -15.83 | -41.735 |
Interest Income (Expense), Net Non-Operating | -0.171 | -0.151 | -0.17 | -0.168 | 0.441 |
Other, Net | -0.729 | 0.521 | -0.599 | 0.005 | -0.4 |
Net Income Before Taxes | -11.116 | -9.958 | -16.648 | -15.993 | -41.694 |
Net Income After Taxes | -11.551 | -11.052 | -17.171 | -18.449 | -42.413 |
Net Income Before Extra. Items | -11.551 | -11.052 | -17.171 | -18.449 | -42.413 |
Net Income | -11.551 | -11.052 | -17.171 | -18.449 | -42.413 |
Income Available to Common Excl. Extra. Items | -11.551 | -11.052 | -17.171 | -18.449 | -42.413 |
Income Available to Common Incl. Extra. Items | -11.551 | -11.052 | -17.171 | -18.449 | -42.413 |
Diluted Net Income | -11.551 | -11.052 | -17.171 | -18.449 | -42.413 |
Diluted Weighted Average Shares | 108.714 | 109.866 | 110.874 | 111.913 | 112.966 |
Diluted EPS Excluding Extraordinary Items | -0.10625 | -0.1006 | -0.15487 | -0.16485 | -0.37545 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.09908 | -0.09941 | -0.15487 | -0.16485 | -0.37545 |
- Annual
- Quarterly
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Total Current Assets | 68.107 | 106.236 | 480.84 | 774.366 | 747.591 |
Cash and Short Term Investments | 47.857 | 65.08 | 424.166 | 663.603 | 587.447 |
Cash & Equivalents | 47.857 | 65.08 | 424.166 | 663.603 | 587.447 |
Total Receivables, Net | 13.341 | 29.566 | 33.371 | 51.208 | 85.254 |
Accounts Receivable - Trade, Net | 13.341 | 28.088 | 33.371 | 51.208 | 85.254 |
Total Inventory | 4.838 | 8.57 | 15.27 | 29.959 | 59.966 |
Prepaid Expenses | 2.071 | 3.02 | 8.033 | 13.029 | 13.896 |
Total Assets | 75.609 | 124.31 | 605.923 | 929.341 | 1018.83 |
Property/Plant/Equipment, Total - Net | 6.925 | 11.127 | 48.821 | 119.823 | 230.41 |
Property/Plant/Equipment, Total - Gross | 17.958 | 25.21 | 67.876 | 150.325 | 279.431 |
Accumulated Depreciation, Total | -11.033 | -14.083 | -19.055 | -30.502 | -49.021 |
Other Long Term Assets, Total | 0.577 | 6.947 | 76.262 | 12.798 | 10.917 |
Total Current Liabilities | 22.141 | 32.362 | 63.049 | 118.126 | 110.357 |
Accounts Payable | 5.443 | 8.792 | 13.028 | 4.709 | 17.351 |
Accrued Expenses | 8.959 | 12.118 | 30.035 | 92.326 | 75.821 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4.224 | 4.187 | 9.882 | 0 | |
Other Current Liabilities, Total | 3.515 | 7.265 | 10.104 | 21.091 | 17.185 |
Total Liabilities | 29.704 | 101.053 | 185.84 | 190.269 | 201.258 |
Total Long Term Debt | 6.335 | 25.489 | 19.837 | 0 | 0 |
Long Term Debt | 6.335 | 25.489 | 19.837 | 0 | |
Other Liabilities, Total | 1.228 | 43.202 | 102.954 | 72.143 | 90.901 |
Total Equity | 45.905 | 23.257 | 420.083 | 739.072 | 817.568 |
Redeemable Preferred Stock | 158.414 | 243.244 | 0 | ||
Common Stock | 0.001 | 0.001 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 6.136 | 11.165 | 682.494 | 1544.22 | 1680.86 |
Retained Earnings (Accumulated Deficit) | -118.631 | -231.116 | -262.367 | -805.098 | -863.321 |
Other Equity, Total | -0.015 | -0.037 | -0.046 | -0.05 | 0.022 |
Total Liabilities & Shareholders’ Equity | 75.609 | 124.31 | 605.923 | 929.341 | 1018.83 |
Total Common Shares Outstanding | 93.8497 | 93.8497 | 96.2416 | 108.486 | 112.515 |
Other Current Assets, Total | 16.567 | 1.028 | |||
Intangibles, Net | 22.354 | 25.397 | |||
Goodwill, Net | 4.511 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 745.716 | 757.174 | 744.104 | 747.591 | 697.335 |
Cash and Short Term Investments | 617.195 | 621.958 | 600.44 | 587.447 | 539.323 |
Cash & Equivalents | 617.195 | 621.958 | 600.44 | 587.447 | 312.487 |
Total Receivables, Net | 57.408 | 59.68 | 78.43 | 85.254 | 76.526 |
Accounts Receivable - Trade, Net | 57.408 | 59.68 | 78.43 | 85.254 | 76.526 |
Total Inventory | 38.507 | 44.087 | 51.141 | 59.966 | 63.697 |
Prepaid Expenses | 14.442 | 13.298 | 14.065 | 13.896 | 17.762 |
Other Current Assets, Total | 18.164 | 18.151 | 0.028 | 1.028 | 0.027 |
Total Assets | 954.033 | 977.579 | 990.572 | 1018.83 | 1003.25 |
Property/Plant/Equipment, Total - Net | 163.666 | 176.454 | 203.304 | 230.41 | 265.88 |
Property/Plant/Equipment, Total - Gross | 198.415 | 215.665 | 247.698 | 279.431 | |
Accumulated Depreciation, Total | -34.749 | -39.211 | -44.394 | -49.021 | |
Goodwill, Net | 4.511 | 4.511 | 4.511 | 4.511 | 4.511 |
Intangibles, Net | 27.342 | 26.693 | 26.041 | 25.397 | 24.764 |
Other Long Term Assets, Total | 12.798 | 12.747 | 12.612 | 10.917 | 10.761 |
Total Current Liabilities | 120.549 | 113.126 | 100.375 | 110.357 | 94.446 |
Accounts Payable | 15.578 | 16.181 | 17.037 | 17.351 | 18.956 |
Accrued Expenses | 95.307 | 85.598 | 69.92 | 75.821 | 59.913 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 9.664 | 11.347 | 13.418 | 17.185 | 15.577 |
Total Liabilities | 201.573 | 192.993 | 190.351 | 201.258 | 196.566 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | ||||
Other Liabilities, Total | 81.024 | 79.867 | 89.976 | 90.901 | 102.12 |
Total Equity | 752.46 | 784.586 | 800.221 | 817.568 | 806.685 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 1569.06 | 1612.23 | 1644.9 | 1680.86 | 1714.86 |
Retained Earnings (Accumulated Deficit) | -816.649 | -827.701 | -844.872 | -863.321 | -905.734 |
Other Equity, Total | 0.048 | 0.058 | 0.194 | 0.022 | -2.443 |
Total Liabilities & Shareholders’ Equity | 954.033 | 977.579 | 990.572 | 1018.83 | 1003.25 |
Total Common Shares Outstanding | 109.589 | 110.74 | 111.537 | 112.515 | 113.276 |
Short Term Investments | 226.836 |
- Annual
- Quarterly
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -18.762 | -112.485 | -31.251 | -542.731 | -58.223 |
Cash From Operating Activities | -10.699 | -76.409 | 34.627 | -217.898 | -21.373 |
Cash From Operating Activities | 4.305 | 3.905 | 7.066 | 14.012 | 21.118 |
Non-Cash Items | 1.81 | 4.156 | 14.048 | 361.202 | 103.177 |
Cash Taxes Paid | 0 | -0.006 | -0.022 | 0.28 | 8.66 |
Cash Interest Paid | 0.658 | 1.824 | 2.25 | 1.67 | 1.222 |
Changes in Working Capital | 1.948 | 28.015 | 44.764 | -50.381 | -87.445 |
Cash From Investing Activities | -3.756 | -6.709 | -42.767 | -38.394 | -106.729 |
Capital Expenditures | -3.756 | -6.709 | -42.767 | -38.394 | -101.278 |
Cash From Financing Activities | 20.583 | 105.367 | 414.59 | 468.906 | 35.297 |
Financing Cash Flow Items | 0 | 0 | -5.848 | -5.028 | |
Issuance (Retirement) of Stock, Net | 20.976 | 86.628 | 414.59 | 506.01 | 40.325 |
Issuance (Retirement) of Debt, Net | -0.393 | 18.739 | 0 | -31.256 | 0 |
Foreign Exchange Effects | -0.014 | -0.018 | -0.045 | -0.463 | 0.234 |
Net Change in Cash | 6.114 | 22.231 | 406.405 | 212.151 | -92.571 |
Other Investing Cash Flow Items, Total | -5.451 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -11.551 | -22.603 | -39.774 | -58.223 | -42.413 |
Cash From Operating Activities | -4.082 | -0.962 | -27.178 | -21.373 | -20.802 |
Cash From Operating Activities | 4.752 | 9.641 | 15.337 | 21.118 | 6.191 |
Non-Cash Items | 17.922 | 47.188 | 74.717 | 103.177 | 28.014 |
Cash Taxes Paid | 6.822 | 7.838 | 8.318 | 8.66 | 2.9 |
Cash Interest Paid | 1.222 | 1.222 | 1.222 | 1.222 | 0.841 |
Changes in Working Capital | -15.205 | -35.188 | -77.458 | -87.445 | -12.594 |
Cash From Investing Activities | -44.316 | -58.884 | -79.111 | -106.729 | -257.558 |
Capital Expenditures | -38.865 | -53.433 | -73.66 | -101.278 | -28.136 |
Other Investing Cash Flow Items, Total | -5.451 | -5.451 | -5.451 | -5.451 | -229.422 |
Cash From Financing Activities | 3.518 | 19.711 | 26.394 | 35.297 | 2.417 |
Financing Cash Flow Items | -5.028 | -5.028 | -5.028 | -5.028 | -5.409 |
Issuance (Retirement) of Stock, Net | 8.546 | 24.739 | 31.422 | 40.325 | 7.826 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
Foreign Exchange Effects | 0.193 | 0.199 | 0.316 | 0.234 | -0.018 |
Net Change in Cash | -44.687 | -39.936 | -79.579 | -92.571 | -275.961 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Morgan Stanley Investment Management Inc. (US) | Investment Advisor/Hedge Fund | 10.0687 | 9625278 | 1765619 | 2022-09-30 | LOW |
Baillie Gifford & Co. | Investment Advisor | 8.9985 | 8602235 | 158847 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.6396 | 8259122 | 446601 | 2022-09-30 | LOW |
Paladin Capital Management, LLC | Investment Advisor | 8.4859 | 8112208 | 0 | 2022-03-31 | |
ARK Investment Management LLC | Investment Advisor | 4.5154 | 4316567 | -260247 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.1947 | 4009979 | -152820 | 2022-09-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 3.8495 | 3679934 | -2314437 | 2022-09-30 | LOW |
Sands Capital Management, LLC | Investment Advisor | 3.5474 | 3391177 | -135701 | 2022-09-30 | LOW |
SRS Investment Management, LLC | Hedge Fund | 3.1439 | 3005427 | 247182 | 2022-09-30 | LOW |
Generation Investment Management LLP | Investment Advisor/Hedge Fund | 2.7257 | 2605677 | -22379 | 2022-09-30 | LOW |
Foresite Capital Management, LLC | Private Equity | 2.6189 | 2503528 | 0 | 2022-09-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.4038 | 2297942 | 959356 | 2022-09-30 | LOW |
Nikko Asset Management Co., Ltd. | Investment Advisor/Hedge Fund | 2.2783 | 2177988 | -29270 | 2022-12-31 | LOW |
Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 2.252 | 2152871 | 468859 | 2022-09-30 | LOW |
Brown Capital Management, LLC | Investment Advisor | 1.6895 | 1615093 | -815862 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.4267 | 1363917 | 26695 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3159 | 1257910 | 38393 | 2022-09-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 1.2069 | 1153705 | 192745 | 2022-09-30 | LOW |
Meritech Capital Partners | Venture Capital | 1.1106 | 1061682 | 0 | 2022-09-30 | LOW |
Baillie Gifford Overseas Ltd. | Investment Advisor | 1.0824 | 1034693 | -24110 | 2022-11-30 | HIGH |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
10x Genomics, Inc. Company profile
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Industry: | Laboratory Diagnostic & Testing Substances |
6230 Stoneridge Mall Road
PLEASANTON
CALIFORNIA 94588
US
Income Statement
- Annual
- Quarterly
News

GBP/USD drops below 1.23 as BOE comments suggest possible end of rate hikes
Despite increasing rates by 50bps at their February meeting, the messaging from the BOE suggests a dovish tilt an the possible end of rate hikes.
15:37, 2 February 2023
Gold latest: XAU/USD rallies on Fed meeting as traders eye Friday’s jobs data
Gold buyers take advantage of risk on sentiment as they eye Friday's NFP data to assess the likelihood of a soft landing
11:48, 2 February 2023
British Pound (GBP) Outlook: GBP/USD, EUR/GBP Ahead of BoE Rate Decision
Bank of England remains a dovish hiker. GBP at risk of another dovish twist
15:13, 1 February 2023
Central Bank Week: Fed, BOE, and ECB meeting previews - USD, EUR, GBP, S&P 500
A lookahead at possible Fed, BOE, and ECB meeting outcomes and market reactions.
14:40, 31 January 2023
FX Weekly Outlook: USD, GBP/USD, EUR/USD Analysis
USD, GBP/USD, EUR/USD forecasts for the week ahead.
16:33, 27 January 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com